ATA Guidelines Tools

Anaplastic Thyroid Cancer ATA 2021

American Thyroid Association Quick-Reference GUIDELINES Apps

Issue link: https://eguideline.guidelinecentral.com/i/1441026

Contents of this Issue

Navigation

Page 20 of 27

21 Palliative Cytotoxic Chemotherapy and/or Radiation Best Supportive Care/Hospice Consider consolidative therapy as feasible** Other tumor genetics? e.g., ALK, NTRK or RET fusions N N Y Y or or Favorable tumor response? Checkpoint inhibitor e.g., pembrolizumab, etc. 1 Targeted therapy (e.g., fusions, ALK: crizotinib, ceritinib, alectinib; RET: pralsetinib, selpercatinib; NTRK: larotrectinib, entrectinib) 1 1 Additional agents exist and are in development, listings not meant to be comprehensive; clinical trials preferred if available; see text. ** Consolidate Rx refers to focal therapy intended to control residual macro-metastatic disease among those electing aggressive therapy. TMB, tumor mutational burden. Dashed arrows depict circumstances where competing therapeutic options may be of consideration.

Articles in this issue

Archives of this issue

view archives of ATA Guidelines Tools - Anaplastic Thyroid Cancer ATA 2021